Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 5/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.50 |
| ▸ | GUSB | P08236 | 2/20 | 0.40 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710610 | 1.00 | GNAI3 (0.50) | GNAI3GNAO1GNAI1GUSBEBP | |
| SCHEMBL23867052 | 1.00 | GNAI3 (0.50) | GNAI3GNAO1GNAI1GUSBEBP | |
| SCHEMBL22460117 | 1.00 | GNAI3 (0.50) | GNAI3GNAO1GNAI1GUSBEBP | |
| SCHEMBL18946832 | 0.98 | GNAI3 (0.49) | GNAI3GNAO1GNAI1GUSB | |
| SCHEMBL18946483 | 0.98 | GNAI3 (0.49) | GNAI3GNAO1GNAI1GUSB | |
| SCHEMBL24792693 | 0.96 | GNAI3 (0.46) | GNAI3GNAO1GNAI1GUSB | |
| SCHEMBL21160561 | 0.94 | GNAI3 (0.44) | GNAI3GNAO1GNAI1GUSB | |
| SCHEMBL26137799 | 0.92 | GNAI3 (0.47) | GNAI3GNAO1GNAI1GUSB | |
| SCHEMBL24489194 | 0.92 | GNAO1 (0.46) | GNAI3GNAO1GNAI1GUSB | |
| SCHEMBL22871198 | 0.92 | GNAO1 (0.46) | GNAI3GNAO1GNAI1GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | Xeniopro GmbH (DE) | 2023-05-11 | — | — | US | disclosed |
| US-9580421-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | AHR, MUSK, TYR | GNAI3 2011/4885GNAO1 2206/4885GNAI1 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.